NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 11, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions

Solid Tumor, AdultMetastatic Nonsmall Cell Lung CancerAnatomic Stage IV Breast Cancer AJCC v8Metastatic Cervical CarcinomaMetastatic Ovarian CarcinomaMalignant Uterine NeoplasmVulvar CancerInvasive Breast CancerMetastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8Recurrent Breast CarcinomaRecurrent Cervical CarcinomaRecurrent Lung Non-Small Cell CarcinomaRecurrent Ovarian CarcinomaRecurrent Vulvar CarcinomaStage IV Cervical Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IV Vulvar Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVA Ovarian Cancer AJCC v8Stage IVA Vulvar Cancer AJCC v8Stage IVB Cervical Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Stage IVB Ovarian Cancer AJCC v8Stage IVB Vulvar Cancer AJCC v8Vulva Squamous Cell Carcinoma

Interventions

OTHER

Blood draws

Blood draws for serum and peripheral blood mononuclear cell isolation collected throughout treatment course

OTHER

QLQ-CIPN20 Survey

20-item self-reported survey for participant reported symptoms related to chemotherapy-induced peripheral neuropathy

OTHER

PR-CTCAE Survey

124-item survey addressing chemotherapy-induced peripheral neuropathy concerning severity of the numbness and tingling and the degree these symptoms interfere with daily activities.

Trial Locations (1)

27157

RECRUITING

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER